Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries

Simple item page
dc.contributor.authorStolbrink, M
dc.contributor.authorChinouya, MJ
dc.contributor.authorJayasooriya, S
dc.contributor.authorNightingale, R
dc.contributor.authorEvans-Hill, L
dc.contributor.authorAllan, K
dc.contributor.authorAllen, H
dc.contributor.authorBalen, J
dc.contributor.authorBeacon, T
dc.contributor.authorBissell, K
dc.contributor.authorChakaya, J
dc.contributor.authorChiang, CY
dc.contributor.authorCohen, M
dc.contributor.authorDevereux, G
dc.contributor.authorEl Sony, A
dc.contributor.authorHalpin, DMG
dc.contributor.authorHurst, JR
dc.contributor.authorKiprop, C
dc.contributor.authorLawson, A
dc.contributor.authorMace, C
dc.contributor.authorMakhanu, A
dc.contributor.authorMakokha, P
dc.contributor.authorMasekela, R
dc.contributor.authorMeme, H
dc.contributor.authorKhoo, EM
dc.contributor.authorNantanda, R
dc.contributor.authorPasternak, S
dc.contributor.authorPerrin, C
dc.contributor.authorReddel, H
dc.contributor.authorRylance, S
dc.contributor.authorSchweikert, P
dc.contributor.authorWere, C
dc.contributor.authorWilliams, S
dc.contributor.authorWinders, T
dc.contributor.authorYorgancioglu, A
dc.contributor.authorMarks, GB
dc.contributor.authorMortimer, K
dc.date.accessioned2024-07-18T12:08:34Z
dc.date.available2024-07-18T12:08:34Z
dc.description.abstractBACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low-and middle-income countries (LMICs), causing avoidable morbidity and mortality. The Inter-national Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022.METHODS: Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis.RESULTS: A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution.CONCLUSION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi -stake-holder, collaborative efforts.
dc.identifier.issn1027-3719
dc.identifier.other1815-7920
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/10980
dc.language.isoEnglish
dc.publisherINT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
dc.subjectDRUG FACILITY
dc.subjectASTHMA
dc.subjectIMPLEMENTATION
dc.subjectAVAILABILITY
dc.subjectCHALLENGES
dc.subjectDISEASE
dc.subjectHEALTH
dc.titleImproving access to affordable quality-assured inhaled medicines in low- and middle-income countries
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu